77
Views
10
CrossRef citations to date
0
Altmetric
Original Research

ypTNM category combined with AJCC tumor regression grade for screening patients with the worst prognosis after neoadjuvant chemoradiation therapy for locally advanced rectal cancer

, , , , , , , , , & show all
Pages 5219-5225 | Published online: 31 Oct 2018

References

  • QuahHMChouJFGonenMPathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiationCancer20081131576418442099
  • ParkIJYouYNAgarwalANeoadjuvant treatment response as an early response indicator for patients with rectal cancerJ Clin Oncol201230151770177622493423
  • RödelCMartusPPapadoupolosTPrognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancerJ Clin Oncol200523348688869616246976
  • SarliLBaderGIuscoDNumber of lymph nodes examined and prognosis of TNM stage II colorectal cancerEur J Cancer200541227227915661553
  • Luna-PérezPRodríguez-RamírezSAlvaradoIGutiérrez de La BarreraMLabastidaSPrognostic significance of retrieved lymph nodes per specimen in resected rectal adenocarcinoma after preoperative chemoradiation therapyArch Med Res200334428128612957524
  • FokasELierschTFietkauRTumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trialJ Clin Oncol201432151554156224752056
  • VecchioFMValentiniVMinskyBDThe relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancerInt J Radiat Oncol Biol Phys200562375276015936556
  • CapirciCValentiniVCioniniLPrognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patientsInt J Radiat Oncol Biol Phys20087219910718407433
  • DhaddaASDickinsonPZaitounAMGandhiNBessellEMPrognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancerEur J Cancer20114781138114521220198
  • ZhangLNXiaoWWXiSYPathological assessment of the ajcc tumor regression grading system after preoperative chemoradiotherapy for chinese locally advanced rectal cancerMedicine2016953e227226817863
  • TrakarnsangaAGönenMShiaJComparison of tumor regression grade systems for locally advanced rectal cancer after multimodality treatmentJ Natl Cancer Inst201410610
  • EdgeSBComptonCCThe American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNMAnn Surg Oncol20101761471147420180029
  • MandardAMDalibardFMandardJCPathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlationsCancer19947311268026868194005
  • BeckerKMuellerJDSchulmacherCHistomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapyCancer20039871521153014508841
  • LowyAMMansfieldPFLeachSDPazdurRDumasPAjaniJAResponse to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancerAnn Surg1999229330330810077040
  • RödelCGrabenbauerGGKühnRCombined-modality treatment and selective organ preservation in invasive bladder cancer: long-term resultsJ Clin Oncol200220143061307112118019
  • BraunOMNeumeisterBPoppWHistologic tumor regression grades in squamous cell carcinoma of the head and neck after preoperative radiochemotherapyCancer1989636109711002492898
  • ShiaJGuillemJGMooreHGPatterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcomeAm J Surg Pathol200428221522315043311
  • SineshawHMJemalAThomasCRMitinTChanges in treatment patterns for patients with locally advanced rectal cancer in the United States over the past decade: An analysis from the National Cancer Data BaseCancer2016122131996200327074300
  • SauerRLierschTMerkelSPreoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 yearsJ Clin Oncol201230161926193322529255